55 completed, 44 terminated, 34 unknown, 17 withdrawn. 183 Phase 2, 37 Phase 1, 28 Phase 3.
Follow Hydroxychloroquine: new trials by email Literature Review of Hydroxychloroquine trials Research Report on Hydroxychloroquine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants Azithromycin 250 mg x3/week (3 tablets/week), Prednisone 10 mg/day, Hydroxychloroquine 400 mg/day - Interstitial Lung Disease | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 30 | 2026-11-01 | 2026-09-22 |
| The Effect of Nicorandil on Rheumatoid Arthritis Patients Nicorandil Oral Tablet, Placebo, conventional synthetic antirheumatic drugs (cDMARDs) - Rheumatoid Arthritis (RA) | Phase 2 / Phase 3 | Recruiting | Ain Shams University | 70 | 2026-09-06 | 2026-09-16 |
| Pilot Study of Hydroxychloroquine for the Treatment of AIMSS Hydroxychloroquine Sulfate (HCQ) - Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain | Phase 2 | Not yet recruiting | Indiana University | 35 | 2026-09-01 | 2026-09-17 |
| AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT Pyrazinamide and Hydroxychloroquine (AI-Optimised), Standard RIPE Regimen (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol) - Pulmonary Tuberculosis | Phase 2 | Not yet recruiting | Ministry of Health, Saudi Arabia | 200 | 2026-09-01 | 2026-03-12 |
| A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus Erythematosus Dihydroartemisinin tablets, Hydroxychloroquine tablets - Discoid Lupus Erythematosus | Phase 2 | Not yet recruiting | Kunming Pharmaceuticals, Inc. | 100 | 2026-04-30 | 2026-04-30 |
| Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma Hydroxychloroquine, Lipiodol, Placebo - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Recruiting | VA Office of Research and Development | 93 | 2026-04-01 | 2026-04-16 |
| Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant Melanoma Tunlametinib, Pucotenlimab, Hydroxychloroquine (HC) - Melanoma Metastatic, NRAS Mutation | Phase 2 | Recruiting | Sun Yat-sen University | 37 | 2026-04-01 | 2026-08-10 |
| Autophagy Maintenance (AUTOMAIN) Hydroxychloroquine, Nelfinavir, Bevacizumab - Ovarian Cancer | Phase 2 | Recruiting | Medical University of South Carolina | 38 | 2025-12-18 | 2025-12-22 |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
| Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study Hydroxychloroquine Oral Tablet, Placebo oral tablet - IgA Nephropathy | Phase 2 | Recruiting | Centre Hospitalier Universitaire de Saint Etienne | 334 | 2025-06-26 | 2026-10-09 |
| A Study to Evaluate Efficacy, Safety and Tolerability of Hydroxychloroquine in Subjects With Parkinson's Disease Hydroxychloroquine (HCQ) - Parkinson&Amp;#39;s Disease | Phase 2 | Active not recruiting | Ottawa Hospital Research Institute | 40 | 2025-06-09 | 2026-10-30 |
| Therapeutic Effect of Upadacitinib in Primary Sjögren's Syndrome Upadacitinib (ABT-494), Hydroxychloroquine (HCQ) - Primary Sjögren's Syndrome (pSS) | Phase 2 | Not yet recruiting | Peking University People's Hospital | 30 | 2025-03-10 | 2025-03-11 |
| Baricitinib in CPPD - the BAPTIST Study Baricitinib 4 MG Oral Tablet, Methylprednisolone (Corticosteroid), Colchicine 1 MG Oral Tablet - Calcium Pyrophosphate Deposition Disease, Chondrocalcinosis | Phase 2 | Not yet recruiting | I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio | 32 | 2025-01-01 | 2025-01-10 |
| Hydroxychloroquine Sulfate Tablets for Radiation-induced Oral Mucositis Hydroxychloroquine Sulfate Tablets, Placebo - Radiation-induced Oral Mucositis | Phase 1 / Phase 2 | Recruiting | Xingchen Peng | 158 | 2024-12-22 | 2025-04-29 |
| Efficacy and Safety of Hydroxychloroquine in the Treatment of Sudden Sensorineural Hearing Loss Hydroxychloroquine, Steroid - Sudden Hearing Loss | Phase 2 | Recruiting | Chang Gung Memorial Hospital | 80 | 2024-09-10 | 2026-10-22 |
| Study on Optimization and Evaluation of Integrated Chinese and Western Medicine for pSS Glandular Damage Yi Qi Yang Yin Decoction, Hydroxychloroquine Sulfate - Primary Sjögren Syndrome | Phase 2 | Enrolling by invitation | Qingwen Tao | 136 | 2024-07-13 | 2024-07-25 |
| Evaluation of Hydroxychloroquine to Prevent CIPN Hydroxychloroquine - Breast Cancer, Gynecologic Cancer | Phase 2 | Withdrawn | University of Arizona | 2024-06-01 | 2024-03-08 | |
| HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer Hydroxychloroquine, Sacituzumab Govitecan, Trastuzumab Deruxtecan - Advanced Breast Cancer, Metastatic Breast Cancer | Phase 1 / Phase 2 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 120 | 2024-01-29 | 2024-03-25 |
| Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis IHL-675A, Cannabidiol, Hydroxychloroquine - Rheumatoid Arthritis | Phase 2 | Terminated | Incannex Healthcare Ltd | 20 | 2023-11-22 | 2026-03-27 |
| Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer Hydroxychloroquine, Irinotecan, Leucovorin - Metastatic Colorectal Cancer | Phase 2 | Active not recruiting | University Health Network, Toronto | 155 | 2023-08-09 | 2026-06-22 |
Showing 20 of 183. Sign in to see all of them.
COVID-19 (62) · Coronavirus Infections (14) · Breast Neoplasms (9) · Pancreatic Neoplasms (8) · Arthritis, Rheumatoid (5) · Carcinoma, Non-Small-Cell Lung (5) · Colorectal Neoplasms (5) · Prostatic Neoplasms (5) · Inflammation (4) · Lupus Erythematosus, Systemic (4) · Severe Acute Respiratory Syndrome (4) · Arthralgia (3) · Arthritis (3) · Lung Diseases, Interstitial (3) · Lung Neoplasms (3)
Abramson Cancer Center at Penn Medicine (9) · Rutgers, The State University of New Jersey (7) · Assistance Publique - Hôpitaux de Paris (4) · NYU Langone Health (4) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · ProgenaBiome (3) · University of Medicine and Dentistry of New Jersey (3) · Cairo University (2) · Columbia University (2) · M.D. Anderson Cancer Center (2) · Massachusetts General Hospital (2) · Medical University of South Carolina (2) · Memorial Sloan Kettering Cancer Center (2) · Nathan Bahary, MD (2) · National University Hospital, Singapore (2)
United States (94) · France (11) · China (10) · Canada (8) · United Kingdom (5) · Australia (4) · Italy (4) · Germany (3) · Brazil (2) · Egypt (2) · Iran (2) · Pakistan (2) · Russia (2) · Saudi Arabia (2) · Singapore (2)
Angela DeMichele, MD (3) · Ravi Amaravadi, MD (3) · Sabine Hazan, MD (3) · Herbert Zeh, MD (2) · Jeffrey L Carson, MD (2) · Joseph Aisner, MD (2) · Sukeshi Patel Arora, MD (2) · Adam Spivak, MD (1) · Alfredo Hernandez-Ruiz, MSc (1) · Amy Clark, MD (1) · Andreas Barratt-Due, MD, PhD (1) · Anne Margarita Dyrhol Riise, MD, Professor (1) · Anthony Joshua, MBBS(Hons) PhD (1) · Ashutosh M. Shukla, MD MBBS (1)
PMID 29929491, PMID 34473343, PMID 12719004, PMID 15366588, PMID 15688692, PMID 16499032, PMID 17825510, PMID 20561931, PMID 21550310, PMID 22985607, PMID 24184265, PMID 24821822, PMID 24991840, PMID 26375670, PMID 26752081, PMID 26900129, PMID 28420720, PMID 30454753, PMID 30922594, PMID 31120501, PMID 31401903, PMID 31428515, PMID 31610260, PMID 31852507, PMID 31936284, PMID 32065348, PMID 32109013, PMID 32112977, PMID 32145363, PMID 32150360, PMID 32150748, PMID 32165426, PMID 32170559, PMID 32171076, PMID 32222346, PMID 32228825, PMID 32247925, PMID 32268923, PMID 32303365, PMID 32425051, PMID 32493468, PMID 32493478, PMID 32497319, PMID 32522282, PMID 32618282, PMID 32650818, PMID 32674792, PMID 32681228, PMID 32736597, PMID 32738928
P30CA072720 (7), 2008 (2), P30CA060553 (2), P30CA012197 (1), P30CA014089 (1), P30CA138292 (1), R01CA181450 (1), U01AR071077 (1), U01CA062475 (1), U10CA180820 (1), UC4DK106993 (1), UC4DK117009 (1), UM1CA081457 (1)